OncLive.comOvjeren akaunt

@OncLive

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

New Jersey, USA
Vrijeme pridruživanja: svibanj 2009.

Tweetovi

Blokirali ste korisnika/cu @OncLive

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OncLive

  1. Prikvačeni tweet
    29. sij

    We spoke with and of about remaining questions in immunotherapy and targeted therapy for advanced in this week's

    Poništi
  2. Nivolumab plus ipilimumab in the frontline setting for patients with advanced led to an improvement in overall survival over chemotherapy, regardless of PD-L1 expression

    Poništi
  3. Over the past few years, substantial progress has been made in the understanding and development of systemic therapies in care; however, the impact of these advancements on surgical care has only come to light recently

    Poništi
  4. The emergence of CDK4/6 inhibitors has impacted treatment decisions for patients with HR+, HER2- , allowing for more options and leading to more investigational efforts

    Poništi
  5. Data suggest that baseline T-cell clonality and exhaustion markers have significant translational relevance and can serve as prognostic factors of response to pembrolizumab as maintenance therapy in metastatic

    Poništi
  6. Risk status should be used to help decide whether premenopausal women with early-stage HR+ need more intensive therapy with an aromatase inhibitor

    Poništi
  7. . of reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in

    Poništi
  8. Antonio González-Martín, MD, of Clinica Universidad de Navarra discusses the design and findings of the PRIMA trial in advanced

    Poništi
  9. Katherine D. Crew, MD, of and discusses the updated results of the KATHERINE trial, as well as other data regarding the adjuvant treatment paradigm in early-stage +

    Poništi
  10. . of discusses the growing relevance of genetic testing for men with and those at a high risk of developing the disease

    Poništi
  11. . of discusses the emergence of in oncology and how he anticipates they will change the paradigm

    Poništi
  12. Although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the OCM is more than enough to think about right now

    Poništi
  13. Although the human epidermal growth factor receptor family of receptor tyrosine kinases plays a central role in the development of human cancers, efforts to target its activity therapeutically have focused thus far on 2 of its now famous members

    Poništi
  14. Research Efforts Continue With Radiation Therapy in

    Poništi
  15. We spoke with experts from to gather updates on initiatives in and , including biomarkers and molecular testing

    Poništi
  16. Niraparib Emerges as a Frontline Maintenance Standard in Advanced

    Poništi
  17. Updated Data Refine Adjuvant Paradigm in + Early

    Poništi
  18. proslijedio/la je Tweet

    The State of the Science summit “The Treatment of ” will be held on 2/11 from 5-9pm at the Sofitel Hotel near Medical Center. Presenters include researchers from and other institutions.

    OncLive Summit Flyer
    Poništi
  19. proslijedio/la je Tweet

    Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer. podcast features physicians Lecia Sequist, MD, and Zofia Piotrowska, MD.

    Poništi
  20. Education, Collaboration Key to Increasing Genetic Screening in

    Poništi
  21. Enter US Market, Poised to Impact Treatment

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·